Stock listing

Nanoviricides, Inc.

Selected listing: A2PSNF · LSX · EUR · DE

Nanoviricides, Inc. (LS Exchange: A2PSNF), Health Technology. Latest release Sep 15, 2026: Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next…

A2PSNF:LSXEURDEUpdated October 3, 2026

Ticker: LS Exchange: A2PSNF
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: LS Exchange
Currency: EUR

Latest news from Nanoviricides, Inc.

Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides

September 15, 2026

Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo

September 8, 2026

The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon

August 18, 2026

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak

August 10, 2026

As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola

July 22, 2026

All Nanoviricides, Inc. news →

Research Nanoviricides, Inc.

Nanoviricides, Inc. company profile

View the public company page for Nanoviricides, Inc. on 6ix.

Nanoviricides, Inc. news

Read company news and market updates connected to Nanoviricides, Inc..

Nanoviricides, Inc. investor events

Find investor webinars, events, and replay context for Nanoviricides, Inc..